Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands.

摘要: The objective of this study was to evaluate the ability troglitazone (a thiazolidinedione) and Wy-14,643 clofibrate) inhibit progression non-detectable detectable mammary tumors in rats induced by 7,12 dimethylbenz(a)anthracene (DMBA) when compared those receiving no treatment or tamoxifen. Although not as effective tamoxifen decreasing overall tumor incidence, reduced percentage number malignant that developed both control. Treatment with either regression stasis total volume 40-50% animals, only 10% control 65% treated animals. Moreover, each PPAR ligand preventing additional development. In summary, ligands were more than once detected. However, PPAR-alpha activator, able reduce development administered prior detection.